Under the GSK collaboration, Ambit will employ its proprietary kinase platform to profile kinase target specificity of selected GSK compounds, thereby accelerating the discovery and development of novel drug candidates.
Under the Bristol-Myers Squibb collaboration, Ambit will employ its proprietary kinase platform to characterize the specificity of certain Bristol-Myers Squibb compounds.
Under the Pfizer collaboration, Ambit will employ its proprietary “reverse screening” technology to identify and characterize the protein targets of certain Pfizer drug discovery compounds and thereby elucidate their molecular mechanism of action.
Commenting on the company’s collaborations, Scott Salka, CEO of Ambit, said, “The earnings generated from our partnerships, including our existing multi-year collaboration with Roche, will support the continued development of Ambit’s pipeline of drug candidates for the treatment of stroke and various cancers, the first of which we plan to advance into clinical trials during 2005.”